Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Cochlear (ASX:COH) Reports on Nexa and FY27 Margin Guidance

Cochlear is the world's largest manufacturer of cochlear implants, devices that restore hearing for people with severe to profound hearing loss by directly stimulating the auditory nerve, bypassing damaged parts of the ear that conventional hearing aids cannot help. The company's FY26 results showed …

Sonal Goyal | 29 September 2026

Cynata Therapeutics (ASX:CYP) Reviews Its Pipeline After Osteoarthritis Trial Results

Cynata's core technology is its CymerusManufacturingplatform, which produces mesenchymal stem cells from induced pluripotent stem cells rather than from individual donor tissue. The company has positioned this as a scalable alternative to conventional donor-derived cell therapy manufacturing, since a single starting cell line can …

Sonal Goyal | 29 September 2026

ImpediMed (ASX:IPD) Raises Capital for SOZO Commercialisation

ImpediMed's core technology, SOZO, uses bioimpedance spectroscopy to measure fluid status in the body, with its primary clinical application in detecting and monitoring lymphoedema — a chronic swelling condition that commonly affects cancer survivors following lymph node removal or radiation therapy. Early detection of …

Sonal Goyal | 29 September 2026

Tissue Repair (ASX:TRP) Develops TR987 for Venous Leg Ulcers

Tissue Repair is a clinical-stage biopharmaceutical company developing advanced wound-healing products built around its Glucoprime technology, a proprietary beta-glucan molecule extracted from yeast that is designed to activate macrophages and stimulate the immune response involved in tissue repair and skin regeneration. Its lead candidate, …

Sonal Goyal | 29 September 2026

Argent BioPharma (ASX:RGT) Sets Out a CannEpil Licensing and Debt Transaction

CannEpil is a standardised 20:1 cannabidiol-to-tetrahydrocannabinol oral solution developed for drug-resistant epilepsy. In July 2026, Argent announced a global licensing framework with US$5.5 million of upfront consideration structured as forgiveness of approximately US$5.5 million of Mercer Street convertible debt. The company said completion would …

Sonal Goyal | 29 September 2026

Ceryvyn Therapeutics (ASX:CYV) Shifts Its Development Focus to a Rare Lung Disease

Shareholders approved the name change from Opthea to Ceryvyn Therapeutics in July 2026, and theASX Codechanged from OPT to CYV. The company shifted its development focus from ophthalmology to a programme targeting lymphangioleiomyomatosis (LAM). Its corporate contact details and service arrangements do not by …

Sonal Goyal | 29 September 2026

Immutep (ASX:IMM) Reviews Its LAG-3 Clinical Programme

Eftilagimod alfa, known as efti, is Immutep's lead product candidate, a soluble LAG-3 fusion protein designed to activate antigen-presenting cells and broadly stimulate the immune system's response against tumours. Unlike checkpoint inhibitors that block a single suppressive signal, efti is designed to work upstream, …

Sonal Goyal | 29 September 2026

Imugene (ASX:IMU) Reduces Costs While Developing Azer-cel

Azer-cel is an allogeneic, or off-the-shelf, CD19-directed CAR T-cell therapy being developed for patients with relapsed or refractory diffuse large B-cell lymphoma, and it incorporates interleukin-2 to help support T-cell persistence and activity. Unlike autologous CAR-T therapies manufactured individually from each patient's own cells, …

Sonal Goyal | 29 September 2026

NeuroScientific Biopharmaceuticals (ASX:NSB) Shifts EmtinB Development Focus

EmtinB is a therapeutic peptide that NeuroScientific investigated for possible use in neurodegenerative conditions. The company later said it decided in 2023 to focus EmtinB development on ophthalmology, with local delivery into the eye under evaluation for advanced glaucoma. Preclinical requirements and any future …

Sonal Goyal | 29 September 2026

Global Health (ASX:GLH) Reports a Smaller FY26 EBITDA Loss

Global Health has provided healthcare software since 1993. Its platforms connect clinicians, care teams and consumers, including provider systems and the Lifecard personal health record.

Sonal Goyal | 29 September 2026
Support

Hi! How can we help you today?

Loading…